… In conclusion, motesanib diphosphate may be an effective treatment in some … thyroid
cancer. However, a broader applicability of treatment that inhibits angiogenesis in thyroid cancer …

… However, evidence suggests that motesanib may inhibit thyroid cancer growth through …
Best on-study response to motesanib diphosphate based on Response Evaluation Criteria …

… demonstrate that motesanib inhibited thyroid tumor xenograft … of VEGFR2 and Ret expressed
on tumor cells. These data sug… Motesanib diphosphate in progressive differentiated thyroid …

… thyroid cancer enrolled in a phase I study of motesanib in patients with advanced solid tumors.
Two phase II trials using 125 mg of motesanib diphosphate … -resistant thyroid cancer. The …

… of motesanib diphosphate on Ret kinase activity and on the growth of human medullary thyroid
carcinoma (TT … We also examined potential mechanisms of tumor inhibition in this model. …

… Here we report results from a planned subanalysis of the motesanib thyroid cancer study …
with tumor response and/or progression-free survival (PFS) during motesanib treatment in …

… Motesanib (AMG 706) is an orally administered tyrosine kinase inhibitor (TKI) targeting
the VEGF receptors 1, 2, and 3 (23). In a phase 1 study, motesanib demonstrated antitumor …

… thyroid cancer and advanced disease in differentiated and medullary thyroid cancer, …
aim of this article is to assess the effects of new drug treatment for advanced thyroid cancer. …

… Motesanib diphosphate is an oral inhibitor of the tyrosine … , treatment with 125 mg of
motesanib diphosphate once daily … thyroid carcinoma was a phase II study of motesanib on 93 …

… of tumor response than motesanib dose. The estimated motesanib concentration yielding
tumor … concentrations in differentiated thyroid cancer and medullary thyroid cancer patients. …